Scholar Rock Holding Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Scholar Rock Holding Corporation (SRRK) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2012 that discovers, develops and delivers selective inhibitors targeting the transforming growth factor beta (TGFβ) superfamily of protein growth factors for serious diseases where growth factors play a fundamental role; its investigational product candidates include apitegromab (SRK-015), a selective inhibitor of myostatin activation in phase 3 clinical trials for spinal muscular atrophy in combination with standard therapies, SRK-181, a TGFβ1 inhibitor that has completed phase 1 trials for cancers resistant to checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 therapies, and SRK-439, a myostatin inhibitor in development for cardiometabolic disorders. The company advances therapies across neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy, cardiometabolic disorders, cancer, fibrosis, iron-restricted anemia, idiopathic pulmonary fibrosis and amyotrophic lateral sclerosis, with operations focused in the United States from its headquarters at 301 Binney Street, Cambridge, Massachusetts. In recent developments, Scholar Rock completed topline data readouts from phase 3 trials of apitegromab positioning it for U.S. biologics license application and European marketing authorization application submissions in the first quarter of 2025 and potential U.S. commercial launch in the fourth quarter of 2025; it bolstered its balance sheet with an upsized $345 million follow-on equity offering providing pro forma cash of approximately $463 million as of September 30, 2024; institutional investors including Vanguard Group and Redmile Group significantly expanded stakes in 2024; and the company presented at the Citi Annual Global Healthcare Conference in December 2025 while reporting an update on a third-party manufacturing site in October 2025.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
Three Biotechs That Are Top Takeover Targets
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Scholar Rock Q1 Earnings Call Highlights
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock to Present at the BofA Securities 2026 Health Care Conference
Scholar Rock (NASDAQ:SRRK) COO Keith Woods Sells 10,220 Shares
Scholar Rock (NASDAQ:SRRK) CFO Vikas Sinha Sells 10,410 Shares of Stock
Scholar Rock (NASDAQ:SRRK) Insider Akshay Vaishnaw Sells 12,246 Shares
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating